BioMarin Pharmaceutical | BMRN - Le Coût Des Ventes





Le Coût Des Ventes Changement Date
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
Bayer EUR 5.23B 731M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
Incyte USD 104.5M 16.68M 2026-03
Insmed USD 49.5M 3.34M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
Moderna USD 955M 503M 2026-03
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.14B 618M 2026-03
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
United Therapeutics USD 133.4M 341.3M 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03